4.10.25.1Vertical
General Rheumatology Practices
Independent rheumatology practices treating inflammatory and autoimmune conditions.
Market snapshot
These figures describe Rheumatology (4.10.25), the segment that General Rheumatology Practices sits within — not General Rheumatology Practices on its own.
FragmentationConsolidatingEstimate
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.
Business model & economics
Revenue model
Office reimbursement plus in-office biologic infusion margin
Key economics
- Recurring revenue
- High
- EBITDA margin
- 18–28% with infusion ancillaries
- Capex intensity
- Low
chronic autoimmune care and infusion
Characteristics
- In-office biologic infusion drives ancillary economics.
- Autoimmune prevalence and biologics growth.
- Rheumatologist shortage and emerging MSO interest.
M&A deal context
Deal activityModerate
Who’s acquiring
- Infusion-focused MSO platforms
- PE-backed rheumatology consolidators
- Multispecialty acquirers
What’s driving deals
- Roll-up for infusion ancillary economics.
- Autoimmune and biologics demand.
- Rheumatologist shortage.
Find General Rheumatology Practices acquisition targets
Search Acquisera’s index for companies classified under General Rheumatology Practices (4.10.25.1) and build a targeted deal pipeline.
Search companies